Literature DB >> 3754760

Effect of allopurinol on caffeine disposition in man.

D M Grant, B K Tang, M E Campbell, W Kalow.   

Abstract

Caffeine (5 mg kg-1) was administered orally to two healthy, non-smoking subjects on three separate occasions--before, and during therapy with the xanthine oxidase inhibitor allopurinol at doses of either 300 or 600 mg daily. Plasma and urinary levels of methylxanthines, endogenous oxypurines and allopurinol and its metabolite oxypurinol were measured using h.p.l.c. analyses. Allopurinol treatment caused a specific, dose-dependent inhibition of the conversion of the caffeine metabolite 1-methylxanthine (1X) to 1-methyluric acid (1U). A good correlation was observed in both subjects between the urinary 1U/1X molar ratio and the ratio of endogenous urate to hypoxanthine + xanthine at the different allopurinol doses, supporting the proposal that the 1U/1X molar ratio after caffeine intake provides an in vivo index of xanthine oxidase activity in man.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3754760      PMCID: PMC1400934          DOI: 10.1111/j.1365-2125.1986.tb05222.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Renal function in gout. 3. Estimation of tubular secretion and reabsorption of uric acid by use of pyrazinamide (pyrazinoic acid).

Authors:  A B Gutman; T F Yü; L Berger
Journal:  Am J Med       Date:  1969-10       Impact factor: 4.965

2.  Renal urate transport during variations in urate synthesis in the rat.

Authors:  T H Steele; J L Underwood
Journal:  Pflugers Arch       Date:  1976-12-28       Impact factor: 3.657

3.  Inhibition of urate production by allopurinol.

Authors:  T Spector
Journal:  Biochem Pharmacol       Date:  1977-03-01       Impact factor: 5.858

4.  Human metabolism of [1-methyl-14C]- and [2-14C]caffeine after oral administration.

Authors:  M M Callahan; R S Robertson; M J Arnaud; A R Branfman; M F McComish; D W Yesair
Journal:  Drug Metab Dispos       Date:  1982 Jul-Aug       Impact factor: 3.922

5.  Effects of allopurinol on theophylline metabolism and clearance.

Authors:  J J Grygiel; L M Wing; J Farkas; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

6.  Caffeine disposition after oral doses.

Authors:  M Bonati; R Latini; F Galletti; J F Young; G Tognoni; S Garattini
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

7.  6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir.

Authors:  T A Krenitsky; W W Hall; P de Miranda; L M Beauchamp; H J Schaeffer; P D Whiteman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

8.  Disposition of caffeine and its metabolites in man.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

9.  Inhibition of theophylline metabolism by long-term allopurinol administration.

Authors:  R L Manfredi; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

10.  Allopurinol kinetics.

Authors:  K Hande; E Reed; B Chabner
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

View more
  14 in total

Review 1.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.

Authors:  N R Scott; D Stambuk; J Chakraborty; V Marks; M Y Morgan
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

4.  Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.

Authors:  R O Day; J Miners; D J Birkett; G G Graham; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 5.  Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics.

Authors:  A Anstey
Journal:  J R Soc Med       Date:  1995-03       Impact factor: 5.344

6.  Interaction of smoking, uptake of polycyclic aromatic hydrocarbons, and cytochrome P450IA2 activity among foundry workers.

Authors:  D Sherson; T Sigsgaard; E Overgaard; S Loft; H E Poulsen; F J Jongeneelen
Journal:  Br J Ind Med       Date:  1992-03

Review 7.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

8.  Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity.

Authors:  L J Notarianni; S E Oliver; P Dobrocky; P N Bennett; B W Silverman
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

9.  Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?

Authors:  Alexander Jetter; Martina Kinzig; Michael Rodamer; Dorota Tomalik-Scharte; Fritz Sörgel; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

10.  Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.

Authors:  E Jacqz-Aigrain; E Bessa; Y Medard; Y Mircheva; E Vilmer
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.